$92.33

Last traded 2018-12-21 — delisted

NASDAQ · Healthcare · Medical - Pharmaceuticals

Revenue

$100.1B -0.2% ▼

5Y CAGR: +1.3%

Gross Profit

$8.8B +1.6% ▲

5Y CAGR: +3.6%

Operating Income

$5.5B +8.0% ▲

5Y CAGR: +14.6%

Net Income

$4.5B +32.7% ▲

5Y CAGR: +28.0%

EPS (Diluted)

$7.74 +43.6% ▲

5Y CAGR: +34.5%

EBITDA

$7.3B +0.9% ▲

5Y CAGR: +9.4%

View Full Income Statement

Line Item	FY2013	FY2014	FY2015	FY2016	FY2017
Revenue	$104.1B	$100.9B	$101.8B	$100.3B	$100.1B
YoY Growth	+10.9%	-3.1%	+0.9%	-1.4%	-0.2%
Cost of Revenue	$96.0B	$93.0B	$93.3B	$91.7B	$91.3B
Gross Profit	$8.1B	$7.9B	$8.4B	$8.6B	$8.8B
Gross Margin	7.8%	7.9%	8.3%	8.6%	8.8%
R&D Expenses	$0	$0	$0	$0	$0
SG&A Expenses	$4.6B	$4.3B	$4.1B	$3.5B	$3.3B
Operating Expenses	$4.6B	$4.3B	$4.1B	$3.5B	$3.3B
Operating Income	$3.6B	$3.6B	$4.3B	$5.1B	$5.5B
Operating Margin	3.4%	3.6%	4.3%	5.1%	5.5%
Interest Expense	$596M	$583M	$500M	$695M	$608M
Income Before Tax	$3.0B	$3.1B	$3.9B	$4.4B	$4.9B
Tax Expense	$1.1B	$1.0B	$1.4B	$1000M	$397M
Net Income	$1.8B	$2.0B	$2.5B	$3.4B	$4.5B
Net Margin	1.8%	2.0%	2.4%	3.4%	4.5%
EPS (Diluted)	$2.25	$2.64	$3.56	$5.39	$7.74
EBITDA	$6.1B	$5.9B	$6.7B	$7.3B	$7.3B
Shares Outstanding	822M	759M	695M	631M	583M

Line Item	FY2016 Q4	FY2017 Q1	FY2017 Q2	FY2017 Q3	FY2017 Q4	FY2018 Q1	FY2018 Q2	FY2018 Q3
Revenue	$24.9B	$24.7B	$25.3B	$24.7B	$25.4B	$24.8B	$25.6B	$25.6B
Cost of Revenue	$22.5B	$22.8B	$23.2B	$22.4B	$22.9B	$22.9B	$23.4B	$23.2B
Gross Profit	$2.3B	$1.9B	$2.2B	$2.2B	$2.5B	$1.9B	$2.2B	$2.4B
Gross Margin	9.4%	7.6%	8.5%	9.1%	9.8%	7.6%	8.6%	9.2%
R&D Expenses	$0	$0	$0	$0	$0	$0	$0	$0
SG&A Expenses	$864M	$818M	$783M	$759M	$908M	$918M	$892M	$863M
Operating Expenses	$864M	$818M	$783M	$759M	$908M	$918M	$892M	$863M
Operating Income	$1.5B	$1.1B	$1.4B	$1.0B	$1.6B	$962M	$1.3B	$1.5B
Operating Margin	5.9%	4.3%	5.4%	4.2%	6.2%	3.9%	5.1%	5.8%
Interest Expense	$146M	$146M	$146M	$148M	$168M	$154M	$151M	$151M
Income Before Tax	$1.3B	$915M	$1.2B	$1.3B	$1.4B	$820M	$1.2B	$1.4B
Tax Expense	-$104M	$365M	$435M	$499M	-$902M	$194M	$290M	$277M
Net Income	$1.4B	$546M	$802M	$842M	$2.3B	$623M	$877M	$1.1B
Net Margin	5.8%	2.2%	3.2%	3.4%	9.2%	2.5%	3.4%	4.2%
EPS (Diluted)	$2.34	$0.90	$1.37	$1.46	$4.10	$1.10	$1.55	$1.89
EBITDA	$2.0B	$1.5B	$1.8B	$1.5B	$2.1B	$1.5B	$1.8B	$2.0B
Shares Outstanding	614M	605M	586M	575M	568M	567M	566M	568M

ESRX NASDAQ